News >

Ribociclib Improved PFS for Women with HR+/HER2- Breast Cancer

Jason Harris
Published: Wednesday, Nov 08, 2017

Samit Hirawat, executive vice president and head, Global Drug Development at Novartis Oncology

Samit Hirawat
Topline results from the MONALESSA-7 trial showed that ribociclib (Kisqali) met its primary endpoint for progression-free survival (PFS) in premenopausal women with hormone-receptor (HR)–positive, HER2-negative (HR+/HER2-) advanced or metastatic breast cancer.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication